Last reviewed · How we verify
anti-thymocyte globulin (ATG)
Anti-thymocyte globulin (ATG) works by binding to and depleting T-lymphocytes, which are a type of immune cell.
Anti-thymocyte globulin (ATG) works by binding to and depleting T-lymphocytes, which are a type of immune cell. Used for Prevention of organ rejection in kidney transplant patients, Treatment of aplastic anemia.
At a glance
| Generic name | anti-thymocyte globulin (ATG) |
|---|---|
| Also known as | (Thymoglobulin®, rabbit ATG), Thymoglobulin, Anti-thymocyte globulin (rabbit) (ATG), ATGAM, Thymoglublin |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | Immunosuppressant |
| Target | CD3 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
ATG is a polyclonal antibody that targets the CD3 component of the T-cell receptor, leading to the depletion of T-lymphocytes. This action reduces the immune response and is used to prevent rejection in organ transplant patients. Additionally, ATG has immunosuppressive properties, which can help to reduce inflammation and prevent graft-versus-host disease.
Approved indications
- Prevention of organ rejection in kidney transplant patients
- Treatment of aplastic anemia
Common side effects
- Thrombocytopenia
- Leukopenia
- Anemia
- Nausea
- Vomiting
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-thymocyte globulin (ATG) CI brief — competitive landscape report
- anti-thymocyte globulin (ATG) updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI